title: Effectiveness of sustained-release bupropion in the treatment of smoker patients with cardiovascular disease.
abstract: OBJECTIVE
  To evaluate the effectiveness of and tolerability to sustained-release bupropion, in smokers with cardiovascular diseases treated in a smoking cessation service, as well as to investigate variables predictive of success or failure in smoking cessation.
  
  
  METHODS
  Sustained-release bupropion was prescribed to 100 current smokers with cardiovascular disease for 12 weeks. Patients were followed for 52 week. The variables studied were gender, age, number of cigarettes, exhaled carbon monoxide, nicotine dependence (Fagerstrom Tolerance Questionnaire), depression (Beck Depression Inventory), anxiety (State-Trait Anxiety Inventory), alcohol consumption (Alcohol Use Disorders Identification Test), number of diagnoses other than smoking, adverse events, and use of medications concomitantly with sustained-release bupropion.
  
  
  RESULTS
  Abstinence rate was 50% at week 12 and 25% at week 52. The logistic regression analysis showed that ageing was positively associated with success, whereas the worsening of the condition, as verified by the presence of a higher number of other health conditions associated with smoking, was negatively associated with success.
  
  
  CONCLUSIONS
  We conclude that the prescription of bupropion for smokers with cardiovascular diseases proved to be safe and effective, especially during the treatment period (week 12).
authors.affiliation: Instituto do Coraçúo, Hospital das Clínicas, FM, USP, São Paulo, SP, Brazil. jissa@cardiol.br
authors.forename: Jaqueline Scholz
authors.initials: JS
authors.lastname: Issa
authors.forename: Glória Heloise
authors.initials: GH
authors.lastname: Perez
authors.forename: Jayme
authors.initials: J
authors.lastname: Diament
authors.forename: Angela Giuliana
authors.initials: AG
authors.lastname: Zavattieri
authors.forename: Kátia Ulrich
authors.initials: KU
authors.lastname: de Oliveira
mesh_terms: D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D016642:Bupropion / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications*; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012907:Smoking / Q000009:adverse effects / Q000188:drug therapy*; D016540:Smoking Cessation / Q000379:methods; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003692:Delayed-Action Preparations; D016642:Bupropion